Rallybio Corp

RLYB Nasdaq CIK: 0001739410

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 234 CHURCH STREET, NEW HAVEN, CT, 06510
Mailing Address 234 CHURCH STREET, NEW HAVEN, CT, 06510
Phone 203- 859-3820
Fiscal Year End 1231
EIN 851083789

Financial Overview

FY2025 FY

$858K
Revenue
$106.18M
Stockholders' Equity

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events March 31, 2026 View on SEC
10-K Annual financial report March 16, 2026 View on SEC
3 Initial insider ownership report March 10, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) March 6, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment March 6, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment March 3, 2026 View on SEC
8-K Current report of material events March 2, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment February 27, 2026 View on SEC
4 Insider stock transaction report February 23, 2026 View on SEC
4 Insider stock transaction report February 20, 2026 View on SEC

Annual Reports

10-K March 16, 2026
  • Proposed all-stock merger with Candid Therapeutics expected to close in Q2 2026, aiming for a diversified pipeline and extended cash runway.
  • Positive Phase 2 clinical trial data for lead candidate RLYB116, with Phase 3 pivotal trial initiation planned for mid-2026 and topline data expected in 2028.
View Analysis

Material Events

8-K Strategy Change January 29, 2026
High Impact
  • Aims to boost stock price per share to meet crucial NASDAQ listing requirements.
  • Seeks to make the stock more attractive to a broader range of investors, especially institutional funds.
View Analysis

Insider Trading

SELL 1 insiders 1 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.